Table 6 Societal costs (2012 US real dollars) per early-treatment patient from genetic testing/monitoring for neovascular AMD enabling incremental early-treatment (vs. late-treatment) ranibizumab therapy
From: A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration
Societal costs per NVAMD patient treated with intravitreal ranibizumab therapy | Column A 12-year, societal costs integrating 2nd eye multiplier of 85.7 % | Column B 12-year, societal costs adjusted for 1st and 2nd eye = 48.5 % × 90 % gene testing sensitivitya | Column C 12-year, direct medical costs, adjusted as in Column B |
|---|---|---|---|
Direct ophthalmic medical costs (genetic testing/monitoring of patients) | A. $66,873 (per incremental early-treatment ranibizumab case) | A. $66,873 (per incremental early-treatment ranibizumab case) | A. $66,873 (per incremental early-treatment ranibizumab case) |
Genetic screening for Category 3 AMD patients with one ranibizumab-facilitated early-treatment case per 30.3 screened cases | $57,805 | $57,805 | $57,805 |
1 more ocular (exam/OCT)/year in high-risk genetic cases (22.5Â % of Category 3 cases) | $9068 | $9068 | $9068 |
Direct non-ophthalmic medical costs [39] | B. (−$93,699) | B. (−$40,914) | B. (−$40,914) |
 Decreased depressionb | (−$7169) | (−$3130) | (−$3130) |
 Decreased injuriesb | (−$3793) | (−$1656) | (−$1656) |
 Decreased nursing home admissionsb | (−$22,351) | (−$9759) | (−$9759) |
 Less skilled nursing facility (SNF) costsb | (−$10,193) | (−$4451) | (−$4451) |
 Other decreased Medicare costsb | (−$50,194) | (−$21,917) | (−$21,917) |
Direct non-medical costs (caregiver costs)b [40] | (−$394,929) | (−$172,443) | NA |
Indirect medical costs (employment costs)b [41] | (−$32,288) | (−$14,098) | NA |
Total negative costs | (−$520,917) | (−$227,455) | (−$40,914) |
Total costs | (−$454,044) | (−$160,582) | $25,960 |